Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | The DUSP6-RSK1 pathway: a driver of disease progression in MPNs

Stephen Oh • 27 Aug 2022
Texas MPN Workshop 2022
Myeloproliferative Neoplasms

Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, discusses the promise of targeting the DUSP6-RSK1 pathway in myeloproliferative neoplasms (MPNs), which has shown to be a driver of disease progression. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Stephen Oh

Inflammation and MPNs: targeting inflammation throughout the disease course 0:47
Inflammation and MPNs: targeting inflammation throughout the disease course
Stephen Oh • 22 Aug 2025
RSK1 as an exploitable dependency in MPNs and secondary AML 1:29
RSK1 as an exploitable dependency in MPNs and secondary AML
Stephen Oh • 22 Aug 2025
Targetting aberrant DUSP6-RSK1 signaling in MPNs to avoid treatment resistance & disease progression 1:43
Targetting aberrant DUSP6-RSK1 signaling in MPNs to avoid treatment resistance & disease progression
Stephen Oh • 6 Dec 2024
Leveraging inflammatory cytokine signaling for therapeutic benefit in MPNs
Stephen Oh • 24 Nov 2022

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals